{"version":"1.0","type":"link","title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.","author_name":"Fizazi K 외","author_url":"https://prs-insight.online/author/Fizazi%20K","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/135123","thumbnail_width":1200,"thumbnail_height":630}